Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

scientific article

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI.INSIGHT.93683
P932PMC publication ID5470884
P698PubMed publication ID28614791

P50authorChetan Eknath ChitnisQ5094149
Ruth O PayneQ56441184
James S McCarthyQ64025726
Sean C EliasQ84616864
Eleanor BerrieQ91783433
Alison M. LawrieQ109926029
Thomas D OttoQ30503446
Matthew K. HigginsQ43240638
Simon J. DraperQ47576805
Nick J EdwardsQ55172988
Thomas JørgensenQ56379466
P2093author name stringAlfredo Nicosia
Jing Jin
Ian D Poulton
Sarah Moyle
David Llewellyn
Rachel Roberts
Simone C de Cassan
Adrian Vs Hill
Geneviève M Labbé
Sarah E Silk
Kathryn H Milne
Ryan Farid
Willem A de Jongh
Daniel Gw Alanine
Thomas A Rawlinson
A Rushdi Shakri
P2860cites workEvidence and implications of mortality associated with acute Plasmodium vivax malariaQ21032494
Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARCQ21131367
A long neglected world malaria map: Plasmodium vivax endemicity in 2010Q21144495
Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine developmentQ21558777
The Resistance Factor to Plasmodium vivax in BlacksQ22250916
Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium VivaxQ24273364
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAQ24289279
Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line systemQ26700012
Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARCQ27670749
Plasmodium vivax Controlled Human Malaria Infection - Progress and ProspectsQ28066456
Plasmodium vivax vaccine research - we've only just begunQ28079136
The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic VariantsQ28396379
Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsQ28731894
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsQ28744149
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.Q33350210
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodiesQ33676028
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposureQ34257253
Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51Q34546201
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trialQ34600955
A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.Q34734075
A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeysQ34978590
Antibody responses and avidity of naturally acquired anti-Plasmodium vivax Duffy binding protein (PvDBP) antibodies in individuals from an area with unstable malaria transmissionQ35031922
Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strainsQ35054176
De novo assembly of a field isolate genome reveals novel Plasmodium vivax erythrocyte invasion genesQ35068049
Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytesQ35460685
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectorsQ35623459
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vectorQ35741984
Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodiesQ35805433
Plasmodium vivax Transmission in AfricaQ35847037
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and EfficacyQ35937418
Independent Origin and Global Distribution of Distinct Plasmodium vivax Duffy Binding Protein Gene DuplicationsQ36178527
Plasmodium vivax but Not Plasmodium falciparum Blood-Stage Infection in Humans Is Associated with the Expansion of a CD8+ T Cell Population with Cytotoxic Potential.Q36215933
A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivaxQ36225497
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adultsQ36347381
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansQ36460499
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infectionQ36751523
Effective induction of high-titer antibodies by viral vector vaccinesQ36770379
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunityQ36835495
Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.Q36867704
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Q36871970
Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding ProteinQ36978206
Targeting the Plasmodium vivax Duffy-binding protein.Q37006600
Red blood cell polymorphism and susceptibility to Plasmodium vivaxQ37058815
A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive ReticulocytesQ37208395
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsQ37229742
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean childrenQ37333369
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infectionQ37641378
Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparumQ37969486
Clinical development of Modified Vaccinia virus Ankara vaccinesQ38092470
Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targetsQ38096489
Recent developments in malaria vaccinologyQ38441542
Development of vaccines for Plasmodium vivax malariaQ38597276
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memoryQ41672361
Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasionQ42051683
Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaquesQ42260871
Malaria vaccine technology roadmapQ43650366
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malariaQ44164504
Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.Q46926980
Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infectionQ47812027
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humansQ47911727
Targeting TLRs expands the antibody repertoire in response to a malaria vaccineQ47986739
Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasionQ48004710
Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population.Q48013929
Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II.Q48019458
P433issue12
P921main subjectPlasmodium vivaxQ311376
P577publication date2017-06-15
P1433published inJCI insightQ27727187
P1476titleHuman vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies
P478volume2

Reverse relations

cites work (P2860)
Q98187263A Humanized Mouse Model for Plasmodium vivax to Test Interventions that Block Liver Stage to Blood Stage Transition and Blood Stage Infection
Q89655220A Plasmodium vivax experimental human infection model for evaluating the efficacy of interventions
Q89790993Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity
Q64967806Born to sweet delight: Using natural models of malaria protection to understand and neutralize P. falciparum pathogenesis.
Q92727025Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7)
Q56342168Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan
Q92797716Human antibodies against DBP
Q47279598Human genetics of infectious diseases: Unique insights into immunological redundancy
Q47576664Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions
Q92827824Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein
Q56358725IgG Responses to the Plasmodium falciparum Antigen VAR2CSA in Colombia Are Restricted to Pregnancy and Are Not Induced by Exposure to Plasmodium vivax
Q56362064Malaria Vaccines: Recent Advances and New Horizons
Q57299814Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial
Q96607419Malaria vaccines since 2000: progress, priorities, products
Q59800434Novel Strategies for Malaria Vaccine Design
Q55382338Persistence of Long-lived Memory B Cells specific to Duffy Binding Protein in individuals exposed to Plasmodium vivax.
Q64947201Rapid and iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P. vivax research.
Q65937995Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody
Q92325722Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP
Q55429433Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1.
Q92447357The acquisition of long-lived memory B cell responses to merozoite surface protein-8 in individuals with Plasmodium vivax infection
Q89802320The enigmatic mechanisms by which Plasmodium vivax infects Duffy-negative individuals